Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook: strong financial metrics with a cash runway through Q3 2026, positive trial progress, and potential for accelerated approval of Lacutamab. However, uncertainties remain due to potential supply chain issues in ADCs, lack of clear guidance on partnerships, and management's vague responses on future plans. The neutral sentiment reflects balanced positive and negative factors, with no strong catalysts to move the stock significantly.
Key Financial Performance
Cash Position EUR 56.4 million at the end of Q3 2025, providing runway through the end of Q3 2026.
IPH4502 Enrollment Progress Enrollment in the dose escalation part of the study is progressing very well, with completion expected by late 2025 or early 2026. Early signs of clinical activity have been observed.
Monalizumab PACIFIC-9 Trial Enrollment Fully completed enrollment with 999 patients randomized 1:1:1 across 3 treatment arms. The independent data monitoring committee recommended continuation of the trial following a preplanned analysis.
Lacutamab TELLOMAK Phase II Data for Sézary Syndrome Global overall response rate of 42.9%, median duration of response of 25.6 months, and median progression-free survival of 8.3 months. Lacutamab was well tolerated with a favorable safety profile.
Lacutamab TELLOMAK Phase II Data for Mycosis Fungoides Global overall response rate of 19.6%, median duration of response of 13.8 months, and median progression-free survival of 10.2 months. Lacutamab was well tolerated with an excellent safety profile.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Lacutamab: FDA clearance received for TELLOMAK-3 Phase III trial in cutaneous T-cell lymphoma (CTCL). Study initiation expected in H1 2026, targeting accelerated approval in Sézary syndrome. Long-term follow-up data from Phase II TELLOMAK trial showed 42.9% overall response rate in Sézary syndrome and 19.6% in mycosis fungoides. Potential market opportunity of $150M in the U.S. for Sézary syndrome, expanding to $500M with mycosis fungoides.
IPH4502: First-in-human trial progressing well with dose escalation expected to complete by Q1 2026. Early signs of clinical activity observed. Differentiated ADC targeting Nectin-4 with potential in bladder cancer and other solid tumors.
Monalizumab: Phase III PACIFIC-9 trial for non-small cell lung cancer fully enrolled with 999 patients. Data expected in H2 2026. Collaboration with AstraZeneca includes up to $825M in milestones, with $450M already received.
CTCL Market Expansion: Lacutamab targets Sézary syndrome and mycosis fungoides, with a combined market potential of $500M in the U.S. and Europe. Initial focus on specialized centers for Sézary syndrome, expanding to broader CTCL indications.
Streamlining Operations: Strategic focus on high-value clinical assets (IPH4502, lacutamab, monalizumab) and advancing next-generation ADC programs. Organization streamlined to align with strategic objectives.
Focused Investment Strategy: Prioritizing investment in IPH4502, lacutamab, and monalizumab to maximize impact and value creation. Building foundation for future innovation through ADC research.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Clinical Trial Risks: The company faces risks related to the successful execution of clinical trials, including the TELLOMAK-3 Phase III trial for lacutamab and the PACIFIC-9 Phase III trial for monalizumab. Delays in enrollment, unforeseen safety issues, or failure to meet primary endpoints could impact regulatory approvals and commercialization timelines.
Market and Commercialization Risks: The commercial success of lacutamab depends on its ability to gain adoption as a second-line treatment for Sézary syndrome and mycosis fungoides. There is a risk that physicians may not adopt lacutamab as a preferred treatment, or that the market size may be overestimated due to challenges in assessing the true incidence and prevalence of CTCL.
Competitive Pressures: The company operates in a highly competitive oncology market. Competitors may develop more effective or better-tolerated therapies, which could limit the market potential of Innate Pharma's products, including lacutamab, IPH4502, and monalizumab.
Financial Risks: With a cash position of EUR 56.4 million, the company has runway only through Q3 2026. Failure to secure additional funding or achieve key milestones could jeopardize ongoing operations and strategic objectives.
Strategic Execution Risks: The company is focusing its resources on three high-value clinical assets. Any misstep in prioritization, resource allocation, or execution could dilute the impact of its strategy and delay value creation.
Supply Chain and Manufacturing Risks: The development and commercialization of antibody-drug conjugates (ADCs) like IPH4502 require complex manufacturing processes. Any disruptions in the supply chain or manufacturing could delay clinical trials and product launches.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Lacutamab Development and Commercialization: - FDA clearance received for TELLOMAK-3 Phase III trial in cutaneous T-cell lymphoma (CTCL), with initiation expected in H1 2026.
- Filing for accelerated approval in Sézary syndrome anticipated post-enrollment milestones.
- Confirmatory Phase III trial to support full approval in 2029 for Sézary syndrome and mycosis fungoides.
- Potential market opportunity of $150 million in the U.S. for Sézary syndrome, expanding to $500 million with mycosis fungoides approval.
- Broader opportunity in early-stage CTCL and peripheral T-cell lymphoma (PTCL).
IPH4502 (Nectin-4 ADC): - Enrollment in Phase I trial progressing well, with dose escalation completion expected by Q1 2026.
- Early signs of clinical activity observed, targeting bladder cancer and other solid tumors with low to medium Nectin-4 expression.
- Potential to address unmet needs in PADCEV-resistant urothelial cancer.
Monalizumab (in collaboration with AstraZeneca): - PACIFIC-9 Phase III trial for unresectable non-small cell lung cancer fully enrolled with 999 patients.
- Top-line data expected in H2 2026.
- Collaboration includes up to $825 million in milestones, with $450 million already received.
Financial Outlook: - Cash position of EUR 56.4 million as of Q3 2025, providing runway through Q3 2026.
- Key milestones expected in 2026 include Phase I data for IPH4502, PACIFIC-9 Phase III data, and initiation of TELLOMAK-3 Phase III trial.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What would you need to get done in the near term for the potential lacutamab commercial launch in Sézary syndrome?
A:The key task is to ensure that lacutamab is included in the NCCN guidelines for Sézary syndrome and mycosis fungoides. Discussions with KOLs have already started to achieve this before the BLA approval.
Q:For IPH4502 and the upcoming data set, could you give more details on what we can see at that readout?
A:The aim is to have data from a cohort of 10+ patients in the PADCEV-resistant setting, showing clinical activity and safety. Additionally, data from 1-2 other tumor types with 10+ patients each is expected. The study is designed to chase signals and backfill cohorts to substantiate findings.
Q:Is FDA looking for any additional supplementary analyses beyond the existing Phase II data set for lacutamab's accelerated approval package?
A:No, the FDA has not indicated a need for further substantial analysis. The BLA approval will be based on the TELLOMAK study data and results that led to the breakthrough therapy designation. The key requirement is to have the confirmatory Phase III study underway with an established enrollment trajectory.
Q:Do you sense growing momentum from KOLs for lacutamab to become the preferred second-line option?
A:Yes, there is growing momentum. KOLs have expressed excitement, particularly for mycosis fungoides (MF), where lacutamab could prevent progression and improve survival rates. It is expected to be used ahead of mogalizumab in MF and post-mogalizumab in Sézary syndrome.
Q:What is your CMC readiness for lacutamab's commercial scale manufacturing?
A:The company is in a good place and ready to go. CMC readiness will not be a critical path to the BLA submission.
Q:Does the plan to file the accelerated approval application by the end of 2026 mean you are still hoping to get a partner on board?
A:Yes, having FDA acceptance of the protocol was important for progressing partnering discussions. The company is keeping options open and evaluating financial opportunities to support growth initiatives.
Q:What specific safety signals are you looking out for in IPH4502, and how do you plan to differentiate it from other TOPO1 inhibitor ADCs?
A:The focus is on avoiding MMA-specific adverse events like peripheral neuropathy and ocular toxicity. So far, no significant trends in these adverse events have been observed. The goal is to establish a favorable benefit-to-risk ratio with a good safety profile.
Q:What is the thought process for the ANKET platform, and what are the long-term plans?
A:The company is finalizing the study for IPH6501 and evaluating clinical data for IPH6101. Future decisions will be based on clinical data expected in the first half of next year. However, the focus remains on advancing IPH4502, lacutamab, and monalizumab.
Q:What are the expectations for the monalizumab readout in the second half of 2026?
A:Expectations are based on the COAST study, where adding monalizumab to durvalumab added 12 months median PFS. If a proportion of this effect size is retained in the PACIFIC-9 study, there is a high chance of a positive outcome.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the long-term plans for the ANKET platform, stating that decisions will be based on future clinical data. Additionally, while they mentioned keeping options open for partnering, they did not provide clear insights into the progress or likelihood of securing a partner.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Communication Commercial
II TELLOMAK
II study
III trial
IPH monalizumab
KOL event
MF
NeoCOST
Phase II
Phase III
Relations Communication
Stage
TELLOMAK Phase
arm
center
cohort patient
derisk
durvalumab
endpoint progression
footprint
incidence
lacutamab KOL
market
model IPH
mogamolizumab
mogamulizumab opportunity
mucosis
opportunity lacutamab
opportunity mycosis
patient mogamulizumab
patient treatment
population
prevalence
profile lacutamab
progression survival
segment
subtype
treatment option
world
IPHA Transcript
Innate Pharma S.A. (IPHA) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call summary presents a mixed picture. While there is a positive revenue increase and reduced net loss, the absence of a shareholder return plan and increased operating expenses are concerns. The strategic initiatives and partnerships, especially with AstraZeneca, are promising but come with risks and uncertainties. The lack of clarity in management responses during the Q&A also adds to the uncertainty. Overall, the sentiment is neutral, with balanced positive and negative factors.
Innate Pharma S.A. (IPHA) Q4 2025 Earnings Call Transcript
Unknown3-26
The earnings call presents a mixed picture. While there are positive developments in clinical trials and partnerships, there are risks associated with trial outcomes and partnership dependencies. Financials show reduced R&D expenses, but operating expenses remain high, and cash position is stable. The Q&A reveals interest in IPH4502 and MATISSE programs, but management's lack of clarity on certain details introduces uncertainty. Overall, the sentiment is balanced by positive clinical progress and financial stability, offset by risks and unclear guidance, suggesting a neutral stock price reaction in the short term.
Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call presents a mixed outlook: strong financial metrics with a cash runway through Q3 2026, positive trial progress, and potential for accelerated approval of Lacutamab. However, uncertainties remain due to potential supply chain issues in ADCs, lack of clear guidance on partnerships, and management's vague responses on future plans. The neutral sentiment reflects balanced positive and negative factors, with no strong catalysts to move the stock significantly.
Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call Transcript
Unknown9-17
The earnings call highlighted several concerns: financial constraints with a limited cash runway, significant operating expenses, and dependency on a few key programs. While there were collaborations with major companies, the lack of diversification and potential regulatory hurdles for key drugs add risks. The Q&A revealed uncertainties about strategic refocus and financial impacts, with management avoiding specific answers, raising investor concerns. Overall, the company's challenges and lack of clear positive catalysts suggest a negative stock price movement.
IPHA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
